Ribupatide
Sources
registry, as of 2026-10-06Stale
https://clinicaltrials.gov/study/NCT07284875
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 2530. Conditions Obesity; Overweight. The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
ClinicalTrials.gov NCT07284875 protocol and results modules
registry, as of 2026-10-06Stale
https://clinicaltrials.gov/study/NCT07284901
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 1270. Conditions Obesity With Diabetes; Overweight With Diabetes. The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
ClinicalTrials.gov NCT07284901 protocol and results modules
registry, as of 2026-08-13Stale
https://clinicaltrials.gov/study/NCT07670884
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects. Overall status RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 675. Conditions Chronic Management of Body Weight. This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
ClinicalTrials.gov NCT07670884 protocol and results modules
registry, as of 2025-07-11Stale
https://clinicaltrials.gov/study/NCT06396429
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese. Overall status COMPLETED. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 567. Conditions Overweight or Obesity. The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
ClinicalTrials.gov NCT06396429 protocol and results modules
registry, as of 2026-07-17Stale
https://clinicaltrials.gov/study/NCT07709910
A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 382. Conditions Participants With Obesity and Knee Osteoarthritis. The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
ClinicalTrials.gov NCT07709910 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT06994650
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 144. Conditions Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy. This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
ClinicalTrials.gov NCT06994650 protocol and results modules
registry, as of 2025-11-17Stale
https://clinicaltrials.gov/study/NCT06974851
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 140. Conditions Bstructive Sleep Apnea (OSA) and Obesity. A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
ClinicalTrials.gov NCT06974851 protocol and results modules
registry, as of 2026-07-15Stale
https://clinicaltrials.gov/study/NCT07458269
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Kailera. Enrollment 264. Conditions Obesity. The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
ClinicalTrials.gov NCT07458269 protocol and results modules
registry, as of 2026-10-22Stale
https://clinicaltrials.gov/study/NCT05881837
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 249. Conditions Overweight or Obesity. This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.
ClinicalTrials.gov NCT05881837 protocol and results modules
registry, as of 2025-11-24Stale
https://clinicaltrials.gov/study/NCT06391710
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 203. Conditions Heart Failure With Preserved Ejection Fraction. This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. A total of 200 obese subjects
ClinicalTrials.gov NCT06391710 protocol and results modules
publication, as of 2026-11-03
https://pubmed.ncbi.nlm.nih.gov/42764407/
clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Preclinical assessments of ribupatide included in vitro functional recept
PMID 42764407